Page 124 - Read Online

Jiang et al. J Transl Genet Genom 2021;5:323-40 https://dx.doi.org/10.20517/jtgg.2021.21 Page 337

11. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94. DOI PubMed
12. Fox CP, Civallero M, Ko Y, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort
study from the international T-cell Project. Lancet Haematol 2020;7:e284-94. DOI PubMed
13. Huang Y, de Reyniès A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal
NK/T-cell lymphoma, nasal type. Blood 2010;115:1226-37. DOI PubMed PMC
14. Montes-Mojarro IA, Chen BJ, Ramirez-Ibarguen AF, et al. Mutational profile and EBV strains of extranodal NK/T-cell lymphoma,
nasal type in Latin America. Mod Pathol 2020;33:781-91. DOI PubMed
15. Li Z, Xia Y, Feng L, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol
2016;17:1240-7. DOI PubMed PMC
16. Lin G, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple
populations. Lancet Oncol 2020;21:306-16. DOI PubMed
17. Peng RJ, Han BW, Cai QQ, et al. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell
lymphoma. Leukemia 2019;33:1451-62. DOI PubMed PMC
18. Xiong J, Cui BW, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell
2020;37:403-419.e6. DOI PubMed
19. Lee SH, Singh I, Tisdale S, Abdel-Wahab O, Leslie CS, Mayr C. Widespread intronic polyadenylation inactivates tumour suppressor
genes in leukaemia. Nature 2018;561:127-31. DOI PubMed PMC
20. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in
myeloma. Blood 2016;128:1735-44. DOI PubMed PMC
21. Dong G, Li Y, Lee L, et al. Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic
roles of PRDM1. Haematologica 2021;106:2427-38. DOI PubMed PMC
22. Kallies A, Carotta S, Huntington ND, et al. A role for Blimp1 in the transcriptional network controlling natural killer cell maturation.
Blood 2011;117:1869-79. DOI PubMed
23. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell
neoplasms by genomic and functional analyses. Blood 2011;118:3195-204. DOI PubMed
24. Küçük C, Iqbal J, Hu X, et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci U S A
2011;108:20119-24. DOI PubMed PMC
25. Desmots F, Roussel M, Pangault C, et al. Pan-HDAC inhibitors restore PRDM1 response to IL21 in CREBBP-mutated follicular
lymphoma. Clin Cancer Res 2019;25:735-46. DOI PubMed
26. Kim BR, Park SH, Jeong YA, et al. RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer.
Oncogene 2019;38:3903-18. DOI PubMed
27. Haider A, Steininger A, Ullmann R, et al. Inactivation of RUNX3/p46 promotes cutaneous T-Cell lymphoma. J Invest Dermatol
2016;136:2287-96. DOI PubMed
28. Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC
gene rearrangement in lymphomas. Am J Surg Pathol 2015;39:294-303. DOI PubMed
29. Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell
lymphoma revealed by gene expression profiling. J Pathol 2011;223:496-510. DOI PubMed
30. Selvarajan V, Osato M, Nah GSS, et al. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by
MYC. Leukemia 2017;31:2219-27. DOI PubMed PMC
31. Chen XJ, Zhang WN, Chen B, et al. Homoharringtonine deregulates. MYC ;116:2220-5. DOI PubMed PMC
32. Jin J, Wang J, Chen F, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a
multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2013;14:599-608. DOI PubMed
33. Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of
histone methyltransferase activity. Blood 2013;121:4512-20. DOI PubMed
34. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Nature 2012;492:108-12. DOI PubMed
35. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell
lymphomas of germinal-center origin. Nat Genet 2010;42:181-5. DOI PubMed PMC
36. Yan J, Li B, Lin B, et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell
lymphoma. Blood 2016;128:948-58. DOI PubMed
37. Li B, Yan J, Phyu T, et al. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-
cell lymphoma. Blood 2019;134:2046-58. DOI PubMed
38. Italiano A, Soria J, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma
and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018;19:649-59. DOI PubMed
39. Patmore DM, Jassim A, Nathan E, et al. DDX3X suppresses the susceptibility of hindbrain lineages to medulloblastoma. Dev Cell
2020;54:455-470.e5. DOI PubMed PMC
40. Phung B, Cieśla M, Sanna A, et al. The X-Linked DDX3X RNA helicase dictates translation reprogramming and metastasis in
melanoma. Cell Rep 2019;27:3573-3586.e7. DOI PubMed
41. Dobashi A, Tsuyama N, Asaka R, et al. Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type. Genes
Chromosomes Cancer 2016;55:460-71. DOI PubMed
42. Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat